Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

NCT00595686 is registered in ClinicalTrials.gov with Esanex Inc. as lead sponsor.

NCT NCT00595686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00595686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-Escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Lead sponsor
Esanex Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
May 31, 2010
Enrollment
25 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic neoplasms